Introduction
============

The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide, and \~25% of adults worldwide suffer from this disease ([@b1-etm-0-0-8465]). It is estimated that in developed countries \~34% of children who are obese may have NAFLD ([@b2-etm-0-0-8465],[@b3-etm-0-0-8465]). Due to the lack of symptoms, NAFLD is challenging to diagnose, and the progression of this disease is unpredictable. Type 2 diabetes mellitus (T2DM) and cardiovascular diseases are reported to be associated with NAFLD, and are the leading causes of mortality in patients with NAFLD ([@b4-etm-0-0-8465],[@b5-etm-0-0-8465]). Basic and clinical studies have shown that NAFLD is detrimental to the health of patients ([@b6-etm-0-0-8465],[@b7-etm-0-0-8465]). Therefore, appropriate therapeutic strategies and drugs are required for the treatment of NAFLD.

NAFLD is characterized by diffuse fatty acid (FA) degeneration and excessive fat accumulation in the liver. Therefore, NAFLD is often accompanied by increased central adiposity and triglycerides (TGs), hyperlipidemia and low levels of high-density lipoprotein (HDL), and this disease is now well recognized as a type of metabolic syndrome ([@b8-etm-0-0-8465],[@b9-etm-0-0-8465]). The mechanisms resulting in the progression of hepatic steatosis are complex, and include increased *de novo* FA generation (lipogenesis), decreased β-oxidation and enhanced non-esterified FA release from adipose tissue (lipolysis) ([@b10-etm-0-0-8465],[@b11-etm-0-0-8465]). Caloric restriction and exercise can improve NAFLD ([@b12-etm-0-0-8465]), but changing lifestyle can be challenging for most patients with NAFLD. To the best of our knowledge, with the exception of diet and lifestyle modifications, no effective treatments for NAFLD are currently available ([@b13-etm-0-0-8465]). Therefore, the identification of effective drugs and investigation of their protective mechanism in the control of lipid levels is required for the treatment of NAFLD.

Atorvastatin (Ato), a lipid-decreasing agent, is the most commonly prescribed statin drug worldwide ([@b14-etm-0-0-8465]), and is used for the treatment of hypercholesterolemia or mixed dyslipidemia. Mechanistically, Ato exerts its protective roles by competitively inhibiting 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase, which is known to suppress the mevalonate pathway and subsequently *de novo* hepatic cholesterol (CHO) synthesis ([@b15-etm-0-0-8465]). Due to the wide application of Ato in clinical settings, other therapeutic properties have been identified in addition to its lipid-decreasing activity, and this drug has been used in the treatment of various disorders, including endothelial dysfunction, cardiovascular disease and depression ([@b16-etm-0-0-8465],[@b17-etm-0-0-8465]). However, studies investigating the ability of Ato to prevent NAFLD are limited, and its molecular mechanisms are not fully understood ([@b18-etm-0-0-8465]). Therefore, it is necessary to examine the potential protective roles and underlying mechanisms of Ato in the treatment of NAFLD in order to identify evidence supporting the clinical application of this drug.

In the present study, golden hamsters were fed with a high-fat diet (HFD) to induce NAFLD. The results suggested that Ato effectively prevented the progression of NAFLD by promoting the AMP-activated protein kinase (AMPK) signaling pathway. However, following AMPK inhibition by Compound C in HepG2 cells, the inhibitory effects of Ato on lipid accumulation were suppressed. The results indicated that Ato may exhibit potential therapeutic properties for the treatment of NAFLD, at least in part, by promoting the AMPK signaling pathway and its downstream targets.

Materials and methods
=====================

### Experimental animals and treatment protocols

Syrian hamsters received humane care according to the Guidelines for the Experimental Laboratory Animal Committee of the Chinese Academy of Medical Sciences and Peking Union Medical College, and the experimental protocols were approved by the Ethics Committee of the Chinese Academy of Medical Sciences and Peking Union Medical College. A total of 24 male Golden Syrian hamsters (age, 8 weeks; weight, 100±10 g) were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd (Beijing, China). Hamsters were housed in a temperature-controlled environment (temperature, 22-2°C; humidity, 55--5%) with a 12-h light/dark cycle and *ad libitum* access to food and water. To increase hepatic lipid accumulation and create the NAFLD model, 16 hamsters were fed with a HFD (20 kcal% protein, 20 kcal% carbohydrate and 60 kcal% fat), while 8 hamsters were fed a normal diet (30 kcal% protein, 60 kcal% carbohydrate and 10 kcal% fat) and served as a control. The diets were obtained from Beijing HFK Bioscience Co., Ltd.

After 2 weeks, 8 hamsters receiving the HFD were administered 3 mg/kg/day Ato via gavage in a volume of 1 mg/ml distilled water for 8 weeks to establish the Ato group ([Fig. 1A](#f1-etm-0-0-8465){ref-type="fig"}). The other 8 hamsters receiving the HFD (model group) and the 8 hamsters in the control group received vehicle instead. The HFD and normal diets were continued during the 8-week treatment period. The daily state of the animals was recorded and their body weight was measured weekly. After 8 weeks of treatment, the animals were anesthetized using urethane (1.2 g/kg body weight), and blood samples were subsequently extracted from the inferior vena cava for analysis. Under anesthesia, the liver tissues were removed, weighed, snap-frozen in liquid nitrogen and stored at −80°C. The coefficient of hepatic weight was calculated as follows: Liver weight (g)/body weight (100 g).

### Reagents

Ato (used in the *in vivo* experiments) was purchased from Pfizer, Inc. CHO, TG, HDL and low-density lipoprotein (LDL) determination kits were purchased from Nanjing Jiancheng Bioengineering Institute. Ato, palmitate (PA) and Compound C (used in the *in vitro* experiments) were purchased from Sigma-Aldrich (Merck KGaA). TRIzol, PrimeScript RT Master mix and SYBR Green Master mix were purchased from Takara Bio, Inc.

### Cell culture and treatment

HepG2 liver cancer cells are a classical cell model utilized in numerous studies to explore abnormalities of lipid metabolism in the liver ([@b17-etm-0-0-8465],[@b19-etm-0-0-8465]). Thus, this cell line was selected for use in *in vitro* experiments. The HepG2 cells (cat. no. 3111C0001CCC000035) were obtained from the Cell Resource Center, Peking Union Medical College (headquarters of the National Infrastructure of Cell Line Resource, NSTI). The identity of the cell lines was authenticated using STR profiling (CODIS; FBI). Cells were cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin, in a 5% CO~2~ atmosphere at 37°C. The cells were plated in six-well plates at 2×10^5^ cells/well. The groups were as follows: i) Control group; ii) PA treated group; HepG2 cells incubated with 250 µM PA at 37°C for 24 h; iii) PA + Ato group; HepG2 cells incubated with 250 µM PA and 10 µM at 37°C for 24 h; iv) PA + Ato + AMPK inhibitor group; Prior to drug treatment, HepG2 cells pre-incubated with 10 µM Compound C at 37°C for 4 h.

### Biochemical analysis

Serum lipid levels, namely CHO, TG, HDL and LDL, were evaluated using the aforementioned commercial kits on an automatic biochemical analyzer (Beckman Coulter, Inc.). Insulin and C-reactive protein (CRP) levels were determined using an INS RIA kit (cat. no. HY-10069) and CRP IRMA kit (cat. no. HY-10023), respectively (Beijing Sino-UK Institute of Biological Technology).

### Hematoxylin and eosin (H&E) staining

Livers were harvested from hamsters, fixed in 4% paraformaldehyde for 24 h (room temperature), embedded in paraffin and sectioned (thickness, 5 µm). The sections were stained with H&E for 10 min (room temperature) and dehydrated. Sections were examined under a light microscope (BX53; Olympus Corporation; magnification, ×200).

### Oil red staining

Oil red O staining was performed as previously described ([@b20-etm-0-0-8465]). Briefly, frozen liver sections (thickness, 5 µm) or HepG2 cells were stained with oil red O working solutions for 30 min, washed with 60% isopropanol and analyzed. ImageJ software (National Institutes of Health, version no. 1.51j8) was used to quantify the results of the oil red O staining of frozen liver sections. TGs were extracted from oil red O-stained HepG2 cells with 100% isopropanol and were analyzed by measuring the optical density at 490 nm.

### Total RNA extraction and reverse transcription-quantitative PCR (RT-qPCR) analysis

Total RNA was extracted from tissues using TRIzol. The purity and concentration of total RNA was measured using a spectrophotometer (Nanodrop 3000; Thermo Fisher Scientific, Inc.). Next, 1,000 ng total RNA was reverse transcribed using a PrimeScript RT Master mix (37°C for 15 min, 85°C for 5 sec, then hold at 4°C). The expression levels of adipose triglyceride lipase (ATGL), lipase E, hormone sensitive type (HSL), pyruvate dehydrogenase kinase 4 (PDK4), carnitine palmitoyltransferase 1A (CPT1a), CPT1b, FA synthase (FASN), stearoyl-CoA desaturase (SCD1), diacylglycerol O-acyltransferase 1 (DGAT1), peroxisome proliferator activated receptor α (PPARα), PPARG coactivator 1 α (PPARGC1A) and GAPDH were analyzed using the CFX-96 Touch Thermocycler with a SYBR Green Master mix. The thermocycling conditions were as follows: Incubation at 95°C for 30 sec, followed by 40 cycles of 95°C for 5 sec, 60°C for 30 sec and 72°C for 30 sec, then dissociation stage. Primer sequences are presented in [Table I](#tI-etm-0-0-8465){ref-type="table"}. The results were normalized to GAPDH and calculated using the 2^−ΔΔCq^ method ([@b21-etm-0-0-8465]).

### Western blot analysis

Western blot assay was performed as previously described ([@b22-etm-0-0-8465]). Briefly, proteins were isolated from cells or tissue samples using RIPA buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS. The protein concentration was measured using BCA Protein Assay Reagent (Thermo Fisher Scientific, Inc.), and 50 µg of protein samples were loaded into 10% gel and were separated by SDS-PAGE, and then transferred to a PVDF membrane. After blocking with 5% non-fat milk in TBST for 2 h at room temperature, the blots were incubated with the primary antibodies at 4°C overnight, including AMPKα (CST; 1:1,000; cat. no. 2532), phosphorylated (p-)AMPKα (CST; 1:1,000; cat. no. 2535), Akt (CST; 1:1,000; cat. no. 9272), p-Akt (CST; 1:1,000; cat. no. 4060), PPARα (Abcam; 1:1,000; cat. no. ab61182), PGC1α (Abcam; 1:1,000; cat. no. ab54481) and GAPDH (Abcam; 1:2,000; cat. no. ab8245). After washing with TBST, membranes were probed with secondary antibody labeled with horseradish peroxidase (Thermo Fisher Scientific, Inc.; 1;5,000; cat. no. 31460) for 1 h at room temperature. The protein bands were detected using enhanced chemiluminescent substrate (Thermo Fisher Scientific, Inc.; cat. no. 34580) and quantified using Image Lab 3.0 (Bio-Rad Laboratories, Inc.).

### Statistical analysis

Data are presented as the mean ± SEM. The statistical significance of differences among groups was assessed by one-way ANOVA followed by the Student-Newman-Keuls test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Ato decreases the body weight and serum lipid levels in golden hamsters

During the 8 weeks of treatment with Ato ([Fig. 1A](#f1-etm-0-0-8465){ref-type="fig"}), the body weights of the golden hamsters from each group were measured. Compared with the control animals, HFD-fed hamsters showed increased body weight, which was significantly attenuated by Ato treatment, indicating that Ato suppressed HFD-induced weight gain ([Fig. 1B](#f1-etm-0-0-8465){ref-type="fig"}).

Serum lipid levels were analyzed at the end of the fourth and eighth weeks of treatment with Ato. After 4 weeks of treatment, the serum levels of CHO, TG and LDL in the model group were markedly increased by 285.33, 680.50 and 735.72%, respectively, in comparison with the control group, indicating that the hamsters in the model group exhibited hyperlipidemia. Following 4 weeks of Ato treatment, CHO, TG and LDL levels were decreased by 55.68, 79.16 and 60.78%, respectively compared with those in the model group ([Fig. 1C](#f1-etm-0-0-8465){ref-type="fig"}). After 8 weeks of Ato treatment, in line with the results of the fourth week, Ato significantly reduced the increased serum levels of CHO, TG and LDL induced by the administration of HFD for 10 weeks ([Fig. 1D](#f1-etm-0-0-8465){ref-type="fig"}).

### Ato decreases the serum levels of insulin and CRP

Previous studies have shown that hyperinsulinemia and increased CRP levels are associated with NAFLD ([@b23-etm-0-0-8465],[@b24-etm-0-0-8465]). The golden hamsters fed with HFD for 6 weeks exhibited increased serum insulin and CRP levels ([Fig. 2A](#f2-etm-0-0-8465){ref-type="fig"}). After 10 weeks of HFD, the serum levels of insulin and CRP in the model group were increased by 101.35 and 80.28% respectively, and these increases were significantly attenuated following Ato treatment ([Fig. 2B](#f2-etm-0-0-8465){ref-type="fig"}).

### Ato reduces the accumulation of lipids in the liver

After 10 weeks of HFD, macroscopic observation of the liver tissue indicated an increased accumulation of lipids in the model group compared with the control group ([Fig. 3A](#f3-etm-0-0-8465){ref-type="fig"}), and this effect was alleviated following treatment with Ato. Additionally, chronic HFD increased liver weight (5.41 vs. 4.56/100 g body weight; [Fig. 3B](#f3-etm-0-0-8465){ref-type="fig"}) and hepatic TG content (15.40 vs. 8.48 µmol/g; [Fig. 3C](#f3-etm-0-0-8465){ref-type="fig"}) compared with the control group. After 8 weeks of Ato treatment, the increased liver weight and TG content were reduced by 9.20 and 29.22%, respectively, indicating that Ato effectively inhibited fat accumulation in the liver.

Possible pathological alterations were further investigated. Results from H&E staining ([Fig. 4A-C](#f4-etm-0-0-8465){ref-type="fig"}) showed that HFD increased hepatic fat accumulation, as the majority of hepatocytes in the livers of HFD-fed hamsters were increased in volume due to the accumulation of fat. Numerous single large adipocytes exhibited displaced nuclei, and ballooning degeneration was evident, and the hepatocytes, which exhibited cytoplasmic vacuolation, were swollen ([Fig. 4B](#f4-etm-0-0-8465){ref-type="fig"}). Oil red O staining results showed that Ato treatment for 8 weeks reduced the accumulation of FAs in the liver compared with that in the model group ([Fig. 4D-F](#f4-etm-0-0-8465){ref-type="fig"}; [Fig. S1](#SD1-etm-0-0-8465){ref-type="supplementary-material"}). The present results suggested that Ato exhibited the ability to inhibit the progression of NAFLD.

### Ato alleviates NAFLD by promoting the expression of genes involved in lipolysis and inhibiting the expression of genes involved in fat synthesis

HFD significantly decreased the hepatic mRNA levels of ATGL and HSL in hamsters to 40 and 58%, respectively, compared with the control group. In addition, HFD suppressed a subset of genes involved in β oxidation, namely CPT1a, CPT1b and PDK4 ([Fig. 5A](#f5-etm-0-0-8465){ref-type="fig"}). Ato reversed the HFD-induced decrease in the hepatic mRNA levels of ATGL and HSL by 225% (P\<0.01) and 122.41% (P=0.09), respectively, and upregulated the reduced mRNA levels of CPT1a, CPT1b and PDK4 induced by HFD treatment, thus promoting adipose lipolysis. Additionally, HFD increased the expression levels of FASN and DGAT1 compared with those in the control group, and these increases were attenuated by Ato treatment ([Fig. 5B](#f5-etm-0-0-8465){ref-type="fig"}). The present results suggested that Ato could increase fat oxidation in the NAFLD model.

### Ato inhibits lipid accumulation via the AMPK-dependent upregulation of PPARα and PGC1α

AMPK is a key molecule involved in the regulation of biological metabolism, and it has been reported to be associated with diabetes and other metabolic diseases. Accumulating evidence has shown that statins can activate the AMPK pathway ([@b25-etm-0-0-8465],[@b26-etm-0-0-8465]). Therefore, the present study aimed to determine whether Ato exerts its protective roles by regulating AMPK ([Fig. 6](#f6-etm-0-0-8465){ref-type="fig"}). Western blotting results showed that the p-AMPK/AMPK and p-Akt/Akt ratios in the livers of HFD-fed hamsters were decreased to 56 and 31%, respectively, of those in the control group ([Fig. 6A](#f6-etm-0-0-8465){ref-type="fig"}). Ato treatment for 8 weeks significantly upregulated the p-AMPK/AMPK and p-Akt/Akt ratios in the liver by 1.91- and 2.42-fold, respectively, compared with those in the model group ([Fig. 6B](#f6-etm-0-0-8465){ref-type="fig"}). In addition, Ato was found to suppress the lipid accumulation in HepG2 cells induced by treatment with 200 µM PA for 24 h ([Fig. 6D](#f6-etm-0-0-8465){ref-type="fig"}). In line with the present *in vivo* results, the phosphorylation ratio of AMPK was decreased in PA-treated HepG2 cells, but was upregulated following treatment with 20 µM Ato for 24 h ([Fig. 6E and F](#f6-etm-0-0-8465){ref-type="fig"}). Treatment with 10 µM Compound C, an AMPK inhibitor, for 24 h significantly suppressed the protective effects of Ato as an inhibitor of lipid accumulation in PA-treated HepG2 cells. Collectively, the present results indicate that AMPK is one of the main targets of Ato involved in the preventive effects of Ato on NAFLD.

Numerous previous studies have indicated that PPARα is downstream of AMPK and Akt, and that its expression level is regulated by Akt ([@b27-etm-0-0-8465]--[@b29-etm-0-0-8465]). Therefore, the mRNA and protein expression levels of PPARα and PPARGC1A were investigated in the liver tissues of the hamsters in the present study. Western blotting results showed that the protein expression levels of PPARα and PGC1α were decreased to 59.75 and 72.26%, respectively, compared with those in the control group (P\<0.05). Treatment with Ato for 8 weeks upregulated the protein expression levels of PPARα and PGC1α by 1.66- and 2.20-fold, respectively, compared with those in the model group (P\<0.05; [Fig. 6C](#f6-etm-0-0-8465){ref-type="fig"}). Consistent with the western blotting results, the RT-qPCR results showed that Ato significantly promoted the mRNA expression levels of PPARα and PPARGC1A (P\<0.05; [Fig. 6G](#f6-etm-0-0-8465){ref-type="fig"}). Collectively, the present results indicate that Ato exerted its protective effects in preventing NAFLD via the AMPK-dependent upregulation of PPARα and PGC1α.

Discussion
==========

Statins are the most commonly prescribed drugs for the attenuation of hypercholesterolemia by blocking HMG-CoA reductase ([@b30-etm-0-0-8465]). Recent clinical studies have shown that statins can reduce hepatic lipid accumulation, thereby alleviating NAFLD ([@b31-etm-0-0-8465]), but the mechanisms underlying this effect are poorly understood. Animal models of NAFLD induced by HFD ([@b32-etm-0-0-8465],[@b33-etm-0-0-8465]) have been widely used to examine the pathogenesis of NAFLD and to investigate new treatment strategies ([@b34-etm-0-0-8465]). HFD-induced liver disease, in contrast with rifampicin-isoniazid-induced hepatotoxicity ([@b35-etm-0-0-8465]), not only leads to chronic inflammation and liver fibrosis, but also disrupts endoplasmic reticulum calcium homeostasis ([@b36-etm-0-0-8465]--[@b38-etm-0-0-8465]). In the present study, hamsters were given a HFD for 10 weeks and developed hepatic steatosis with high levels of TG, TCH, insulin and CRP, phenocopying the clinical features of human NAFLD. Following Ato treatment, the increased body weight and elevated serum levels of TCH, TG, LDL, insulin and CRP identified in HFD-fed hamsters were decreased. Additionally, the relative liver weight of HFD-fed hamsters treated with Ato was markedly decreased compared with that of the model group. Morphologically, the livers of hamsters in the model group exhibited numerous large lipid droplets and various defects compared with the control group. However, the livers of HFD-fed hamsters treated with Ato exhibited fewer lipid droplets and an improved liver morphology, indicating that Ato exhibited beneficial effects in suppressing lipid accumulation and attenuating the disruption of liver structure.

The prevalence of NAFLD in China is increasing. In 2014, a meta-analysis of epidemiologic studies revealed that the overall prevalence of NAFLD was \~20% in China ([@b39-etm-0-0-8465]). NAFLD has been identified to be associated with obesity, dyslipidemia, insulin resistance and T2DM ([@b40-etm-0-0-8465]). Due to the increase in metabolic risk factors, patients suffering from NAFLD are at higher risk of developing cardiovascular diseases, which are associated with increased morbidity and mortality ([@b41-etm-0-0-8465]). NAFLD contributes to the development of T2DM, non-alcoholic steatohepatitis and hepatocellular carcinoma ([@b42-etm-0-0-8465]). However, the number of targeted drugs to treat NAFLD remain limited. In clinical settings, statins are widely used to reduce the serum levels of lipids, which is considered to suppress NAFLD. However, the number of studies investigating the protective effects of Ato on NAFLD remain limited and its underlying molecular mechanisms are unclear. Therefore, to investigate these questions, an animal model of NAFLD was constructed in the present study, in which golden hamsters were fed a HFD to induce NAFLD. Ato treatment not only decreased the serum levels of TG, TCH, LDL, CRP and insulin, but also attenuated lipid accumulation and pathological alterations, indicating that Ato exhibited the potential to treat NAFLD.

The pathogenesis of NAFLD is complex and involves numerous signaling pathways, including the PI3K/Akt, Toll-like receptor (TLR), apoptosis and mTOR pathways ([@b43-etm-0-0-8465],[@b44-etm-0-0-8465]). Deficient PI3K activity leads to an increase in intracellular FA-derived metabolites ([@b45-etm-0-0-8465]). TLR-4 can activate X-box binding protein-1 and thereby promote the progression of NAFLD ([@b46-etm-0-0-8465]). Increases in active caspase 2, active caspase 3 and apoptosis have been observed in the livers of patients with NAFLD ([@b47-etm-0-0-8465]). Metabolic abnormality of lipids in the liver may cause insulin resistance, inflammation and apoptosis ([@b48-etm-0-0-8465]--[@b50-etm-0-0-8465]).

AMPK regulates numerous metabolic pathways and may have therapeutic potential in the treatment of obesity, insulin resistance, T2DM and NAFLD. Activation of AMPK can inhibit acetyl CoA carboxylase (ACC), which plays crucial roles in lipogenesis. AMPK also regulates FA metabolism in the liver via the regulation of total mitochondrial content and function. Recent studies have indicated that statins may be able to alleviate numerous diseases by regulating the AMPK-mediated pathway, including neurotoxicity, myocardial fibrosis and endoplasmic reticulum stress ([@b51-etm-0-0-8465]--[@b53-etm-0-0-8465]). These previous studies suggest that Ato may protect against NAFLD by increasing the activity of the AMPK signaling pathway.

As an energy sensor that maintains cellular energy homeostasis, AMPK has been reported to positively regulate FA oxidation by activating PPARα and PGC1α ([@b54-etm-0-0-8465]). Additionally, there is evidence to indicate that AMPK activates the PI3K/Akt pathway by inhibiting the phosphorylation of insulin receptor substrate-1 (Ser^636/639^) ([@b55-etm-0-0-8465]--[@b57-etm-0-0-8465]). Hinoi *et al* ([@b58-etm-0-0-8465]) found that the PI3K/Akt pathway could indirectly promote the nuclear translocation of PGC1α, which serves crucial roles in FA oxidation. Consistent with a previous study ([@b59-etm-0-0-8465]), the livers of HFD-fed hamsters in the present study exhibited a significant reduction in AMPK phosphorylation levels compared with the control group. Akt phosphorylation, as well as PPARα and PGC1α protein expression levels were also reduced in the model group compared with the control. However, Ato treatment for 8 weeks significantly reversed the decreased levels of p-AMPK, p-Akt, PPARα and PGC1α, indicating that Ato is able to regulate the expression of AMPK and its downstream targets.

Activation of FA β-oxidation facilitates the metabolism of lipids in the liver. PPARα has been indicated to stimulate FA β-oxidation by increasing the expression level of PDK4 ([@b60-etm-0-0-8465]). Additionally, PPARα controls the constitutive expression of mitochondrial FA β-oxidation enzymes ([@b61-etm-0-0-8465]) and increases the level of uncoupling protein 2 in mitochondria ([@b62-etm-0-0-8465]). Since Ato upregulated PPARα via AMPK and its downstream targets, the present study also investigated the mRNA levels of several genes involved in lipid metabolism, including lipogenesis and β-oxidation. The results revealed that the HFD-induced inhibition of ATGL, HSL, PDK4, CPT1a and CPT1b expression levels could be effectively attenuated by Ato treatment. Collectively, the present data indicate that Ato may promote lipid metabolism via the AMPK-dependent upregulation of PPARα, PGC1α and their target genes.

However, the present study presents certain limitations. The impact the Ato on control mice was not explored in this study. Although Ato may protect against NAFLD by activating AMPK and its target genes, it may have multiple targets in addition to AMPK and HMG-CoA reductase. Furthermore, *in vitro* experiments are required to investigate whether the protective effects of Ato are neutralized following the knockdown of AMPK using small interfering RNA or adenoviral means. Future studies conducted by the present team will aim to investigate this aspect.

In conclusion, the results of the present study suggest that Ato could effectively prevent the progression of NAFLD in a hamster model, as evidenced by its ability to attenuate the HFD-induced increases in serum levels of lipids, insulin and CRP, and by the reduction of lipid accumulation in the liver. Mechanistically, the results also indicate that Ato inhibited fat accumulation in the liver via the AMPK-dependent upregulation of PPARα, PGC1α and their target genes, which are associated with β-oxidation. In conclusion, the present study suggests the potential of Ato as a therapeutic drug for the clinical treatment of NAFLD.
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![Effects of Ato on weight gain and serum lipid levels of golden hamsters fed a HFD. (A) Summary of the experimental design. (B) Body weight of golden hamsters in each group from 0 to 8 weeks of treatment. (C and D) CHO, TG, LDL-c and HDL-c in the serum of golden hamsters following Ato treatment for (C) 4 and (D) 8 weeks. Data are presented as the mean ± SEM (n=8/group). \#\#P\<0.01 vs. control group; \*P\<0.05, \*\*P\<0.01 vs. model group. Ato, atorvastatin; HFD, high fat diet; CHO, cholesterol; TG, triglyceride; LDL, low density lipoprotein; HDL, high density lipoprotein.](etm-19-03-2133-g00){#f1-etm-0-0-8465}

![Effect of Ato on the serum levels of INS and CRP. (A) Serum INS and CRP levels of golden hamsters following Ato treatment for 4 weeks. (B) Serum INS and CRP levels of golden hamsters following Ato treatment for 8 weeks. Data are presented as the mean ± SEM (n=8/group). \#\#P\<0.01 vs. control group; \*P\<0.05, \*\*P\<0.01 vs. model group. Ato, atorvastatin; INS, insulin; CRP, C-reactive protein.](etm-19-03-2133-g01){#f2-etm-0-0-8465}

![Effect of Ato on liver weight and hepatic TG in HFD-fed golden hamsters. (A) Representative images of livers from different groups. (B) Relative liver weight in each group. (C) Hepatic TG level in golden hamsters following Ato treatment for 8 weeks. Data are presented as the mean ± SEM (n=8/group). \#P\<0.05, \#\#P\<0.01 vs. control group; \*P\<0.05, \*\*P\<0.01 vs. model group. Ato, atorvastatin; TG, triglyceride; HFD, high fat diet; BW, body weight.](etm-19-03-2133-g02){#f3-etm-0-0-8465}

![Effect of Ato on lipid accumulation in livers of HFD-fed golden hamsters. (A-C) Hematoxylin and eosin staining of liver tissues from each group under a light microscope (magnification, ×200). (D-F) Oil red O staining of liver tissues from each group under a light microscope (magnification, ×200). Ato, atorvastatin; HFD, high fat diet.](etm-19-03-2133-g03){#f4-etm-0-0-8465}

![Effect of Ato on the mRNA levels of genes involved in lipid metabolism. (A) mRNA levels of genes associated with lipolysis and β-oxidation. (B) mRNA levels of genes associated with fatty acid synthesis. Data are presented as the mean ± SEM (n=8/group). \#P\<0.05, \#\#P\<0.01 vs. control group; \*P\<0.05, \*\*P\<0.01 vs. model group. Ato, atorvastatin; ATGL, adipose triglyceride lipase; HSL, lipase E, hormone sensitive type; PDK4, pyruvate dehydrogenase kinase 4; CPT1a/CPT1b, carnitine palmitoyltransferase 1A/B; FASN, fatty acid synthase; SCD1, stearoyl-CoA desaturase; DGAT1, diacylglycerol O-acyltransferase 1.](etm-19-03-2133-g04){#f5-etm-0-0-8465}

![Ato inhibits lipid accumulation by promoting the AMPK signaling pathway. (A) Representative images of p-AMPK, AMPK, p-Akt, Akt, PPARα and PGC1α western blots. (B) Relative p-AMPK/AMPK, p-Akt/Akt and (C) PPARα/GAPDH and PGC1α/GAPDH protein levels are presented. \#P\<0.05, \#\#P\<0.01 vs. control group; \*P\<0.05 vs. model group. (D) Lipid accumulation in HepG2 cells, quantified by the absorbance value of oil red O reagent at 490 nm. Data are presented as the mean ± SEM (n=6). (E) Representative images of p-AMPK and AMPK in PA-treated HepG2 cells with or without Ato and Compound C treatment. (F) Relative p-AMPK/AMPK protein levels. Data are presented as the mean ± SEM (n=3). \#\#P\<0.01 vs. control group; \*P\<0.05 vs. PA group; ^Δ^P\<0.05 vs. PA + Ato group. (G) mRNA levels of PPARα and PPARGC1A in each group. Data are presented as the mean ± SEM (n=3/group). \#\#P\<0.01 vs. control group; \*P\<0.05 vs. model group. (H) Schematic illustration showing the suggested mechanisms underlying the protective effect of Ato against non-alcoholic fatty liver disease. Ato, atorvastatin; p-, phosphorylated; PPARα, peroxisome proliferator activated receptor α; AMPK, AMP-activated protein kinase; PGC1α, peroxisome proliferator-activated receptor-γ coactivator 1 α; PPARGC1A, PPARG coactivator 1 α; PA, palmitate.](etm-19-03-2133-g05){#f6-etm-0-0-8465}

###### 

Sequences of the primers used for reverse transcription-quantitative PCR.

  Gene name   Forward primer              Reverse primer
  ----------- --------------------------- ----------------------
  ATGL        CACTTTAGCTCCAAGGATGA        TGGTTCAGTAGGCCATTCCT
  HSL         GGTGACACTCGCAGAAGACAATA     GCCGCCGTGCTGTCTCT
  PDK4        CACAGTTGAGCACCAAGA          AGCCTGACATAGAGTAGAGA
  CPT1a       CCACTGATGAAGGAAGGAG         TAGTAGTTGCTGTTGACCAT
  CPT1b       CTCCACAAGCCAGATTCC          ACTCACCGTCTCAGAACT
  FASN        CTTGTCCAGGTTCGTGAG          TGTTGCTTCGGTGATGAG
  SCD1        CTTCACCACATTCTTCATCG        TCCCGTCTCCAGTTCTTT
  DGAT1       GGCATCATACTCCATCATCT        TCTCGGTAGTTCAGATTGTC
  PPARα       GAGAAAGCAAAACTGAAAGCAGAGA   GAAGGGCGGGTTATTGCTG
  PPARGC1A    TGGATGAAGACGGATTGC          GCGACTGTGGTTGTGTAT
  GAPDH       AACAGGGTGGTGGACCTCAT        TGCTCTCAGTATCCTTGCTG

ATGL, adipose triglyceride lipase; HSL, lipase E, hormone sensitive type; PDK4, pyruvate dehydrogenase kinase 4; CPT1a/b, carnitine palmitoyltransferase 1A/B; FASN, fatty acid synthase; SCD1, stearoyl-CoA desaturase; DGAT1, diacylglycerol O-acyltransferase 1; PPARα, peroxisome proliferator activated receptor α; PPARGC1A, PPARG coactivator 1 α.
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